Expected Symptoms in a 22-Year-Old Stem Cell Donor Receiving Filgrastim
A healthy 22-year-old stem cell donor receiving filgrastim should expect bone pain (occurring in approximately 82-84% of donors) and headache (occurring in 54-70% of donors) as the most common symptoms, with fatigue (20-31%) and nausea (10-13%) also frequently reported. These symptoms are generally moderate, manageable with oral analgesics, and resolve within 2-7 days after completing the donation process 1, 2, 3, 4.
Most Common Expected Symptoms
Musculoskeletal Symptoms (Most Prominent)
- Bone pain: Affects 82-84% of donors, typically described as diffuse skeletal discomfort 3, 4
- Back pain and pain in extremities: Common manifestations of the bone pain 1
- Usually responds well to over-the-counter analgesics (approximately 62% of donors require oral pain medication) 4
Neurological Symptoms
Constitutional Symptoms
- Fatigue: Reported in 20-31% of donors 3
- Flu-like symptoms: May occur during the mobilization period
Gastrointestinal Symptoms
- Nausea: Affects approximately 10-13% of donors 3
- Less common than musculoskeletal or neurological symptoms
Timeline and Resolution
The symptom pattern follows a predictable course:
- Symptoms typically begin during filgrastim administration (days 1-5)
- Peak around the time of apheresis collection
- Resolve within 2-7 days after completing the donation in the vast majority of donors 2, 4
- Physical status returns to baseline by day 14 in essentially all peripheral blood stem cell donors 2
Laboratory Changes (Expected and Benign)
The donor will experience predictable hematologic changes 4, 5:
- Eight-fold increase in neutrophil counts (mean white blood cell count reaches approximately 42.8 × 10⁹/L) 3
- Two-fold increase in lymphocyte counts
- Temporary elevation in alkaline phosphatase and lactate dehydrogenase
- Minor changes in potassium, magnesium, and uric acid
- Transient thrombocytopenia immediately post-apheresis (platelet count may drop to ~98 × 10⁹/L but recovers within days) 6, 5
All laboratory abnormalities resolve within 7 days after apheresis 4.
Critical Safety Warnings (Rare but Serious)
While the above symptoms are expected and benign, counsel the donor about rare but serious complications that require immediate medical attention 1:
Immediate Emergency Symptoms
- Left upper abdominal or shoulder pain: May indicate splenic rupture (rare but potentially fatal) 1, 7
- Severe, progressive headache that worsens or wakes from sleep: Could indicate intracranial hemorrhage (extremely rare) 8
- Fever with respiratory symptoms or lung infiltrates: May indicate ARDS 1
- Allergic reactions: Including anaphylaxis, though most occur on first exposure 1
When to Seek Medical Attention
The donor should contact medical staff immediately if experiencing:
- Severe or worsening abdominal pain
- Sudden severe headache different from typical filgrastim-related headache
- Difficulty breathing or chest pain
- Signs of allergic reaction (rash, swelling, difficulty breathing)
Practical Management Approach
For routine expected symptoms:
- Reassure the donor that bone pain and headache are normal and temporary
- Recommend over-the-counter NSAIDs or acetaminophen for pain management
- Advise adequate hydration
- Explain that symptoms will resolve within one week after donation
- No activity restrictions are typically needed for mild-moderate symptoms
Important caveat: While chronic musculoskeletal symptoms are exceedingly rare (only isolated case reports exist) 9, donors should be informed that persistent symptoms beyond 2 weeks warrant medical evaluation, though this occurs in less than 1% of cases.
Comparison to Bone Marrow Donation
Interestingly, the overall symptom burden is similar between peripheral blood stem cell donation with filgrastim and traditional bone marrow harvest, but the timing differs: filgrastim symptoms peak during mobilization and resolve faster (by day 14), while bone marrow donors experience post-procedural pain lasting an average of 14 days 2, 6. Neither procedure requires transfusion or hospitalization in healthy donors 4.
The 22-year-old donor can be reassured that this is a well-tolerated procedure with predictable, self-limited side effects that resolve quickly after donation completion.